Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBIT (2020 - 2025)

Historic EBIT for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $11.3 million.

  • Bioventus' EBIT rose 20852.76% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.4 million, marking a year-over-year increase of 30893.57%. This contributed to the annual value of -$12.0 million for FY2024, which is 8534.23% up from last year.
  • According to the latest figures from Q3 2025, Bioventus' EBIT is $11.3 million, which was up 20852.76% from $18.4 million recorded in Q2 2025.
  • Over the past 5 years, Bioventus' EBIT peaked at $22.0 million during Q2 2021, and registered a low of -$126.8 million during Q4 2022.
  • Its 5-year average for EBIT is -$11.3 million, with a median of $1.2 million in 2023.
  • As far as peak fluctuations go, Bioventus' EBIT plummeted by 1201451.77% in 2022, and later soared by 83725.32% in 2024.
  • Over the past 5 years, Bioventus' EBIT (Quarter) stood at -$3.2 million in 2021, then crashed by 396.41% to -$15.6 million in 2022, then surged by 107.45% to $1.2 million in 2023, then soared by 837.25% to $10.9 million in 2024, then increased by 3.05% to $11.3 million in 2025.
  • Its EBIT stands at $11.3 million for Q3 2025, versus $18.4 million for Q2 2025 and $4.9 million for Q1 2025.